While Sanofi/Regeneron's sarilumab is set to be the first of the newer IL-6 products to be cleared for rheumatoid arthritis treatment in Europe and the US, its commercial success is under doubt with physicians trying anti-TNF treatments first, followed by Roche's established IL-6 drug Actemra (tocilizumab).
With the European Medicines Agency's CHMP giving Kevzara (sarilumab) a positive opinion, Sanofi/Regeneron Pharmaceuticals Inc.'s IL-6 receptor antagonist is set for EC approval in the coming months. But making it a commercial success will prove to be a challenge.
[Sidebar#PS120377]